Role of Transposable Elements in Septic Immune Aging

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of California, San Francisco

About this trial

The goal of this observational study is to learn about how transposable element levels affect the patient outcomes in sepsis. The main questions it aims to answer is:

1. Do transposable elements prematurely age the immune systems of patients with sepsis? 2. Do transposable elements correlate with increased mortality in patients with sepsis in the ICU? 3. Do transposable elements correlate with increased amount of secondary infections in patients with sepsis in the ICU?

Participants will have blood drawn from them but will not be subjected to additional interventions.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Age 18 or older

Admitted to ICU with sepsis (Sepsis 3 Criteria)

SOFA score of at least 2 at time of enrollment

Disqualifiers

Patients on organ transplantation immunosuppression

Patients with preexisting leukopenia

Cancer patients receiving CAR-T therapy

Patients who are under 18 years of age or otherwise deemed pediatric

Trial population

The study population includes adult patients admitted to the intensive care unit with sepsis with a SOFA score of at least 2. Sepsis is defined by the Sepsis 3 Criteria.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • RNA and DNA Sequencing

    Genetic

    DNA and RNA sequencing will be conducted on both control participants and patients with sepsis who are admitted to the ICU.

Treatment groups

116 Participants
are divided into 2 treatment groups
Group A: Patients with Sepsis1 intervention
Group B: Healthy Individual Controls1 intervention

Trial outcomes

Primary outcomes

1

Immune Aging

Time frame
6 weeks

Secondary outcomes

1

Mortality (30-day)

Time frame
30 days
2

Secondary Infection

Time frame
30 days

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University of California, San Francisco

Lead sponsor

National Cancer Institute (NCI)

Collaborator